Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTechnische Universität Dresden
About this trial
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Eligibility criteria
Qualifiers
Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST
At least 5 years since initial sarcoma diagnosis
With or without active disease
Age ≥18 years at the time of study participation
Disqualifiers
Diagnosis of Desmoid tumors
Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)
Trial design
Treatments tested in this trial
- No intervention (observational study)
Treatment groups
1,600 Participants
are divided into 1 treatment groupSponsors and collaborators
Technische Universität Dresden
Lead sponsor
German Sarcoma Foundation (DSS)
Collaborator
German Cancer Research Center
Collaborator
Universitätsmedizin Mannheim
Collaborator
University Hospital, Essen
Collaborator
National Centre for Tumor Diseases Heidelberg
Collaborator
Source ClinicalTrials.gov